FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs

InflaRx (NASDAQ:IFRX - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2024 EPS estimates for InflaRx in a research report issued on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($1.02) per share for the year, down from their prior estimate of ($0.99). The consensus estimate for InflaRx's current full-year earnings is ($1.01) per share. Leerink Partnrs also issued estimates for InflaRx's Q4 2024 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.01) EPS and FY2026 earnings at ($0.93) EPS.

Separately, HC Wainwright restated a "buy" rating and set a $8.00 target price on shares of InflaRx in a report on Monday.

InflaRx Price Performance

IFRX traded up $0.32 during trading on Thursday, reaching $2.03. The company had a trading volume of 2,062,745 shares, compared to its average volume of 162,421. The business's fifty day moving average price is $1.53 and its 200 day moving average price is $1.51. InflaRx has a 12 month low of $1.17 and a 12 month high of $2.44. The company has a market cap of $119.53 million, a P/E ratio of -1.81 and a beta of 1.57.

Institutional Investors Weigh In On InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC raised its position in InflaRx (NASDAQ:IFRX - Free Report) by 2.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 704,987 shares of the company's stock after acquiring an additional 16,383 shares during the quarter. Ikarian Capital LLC owned approximately 1.20% of InflaRx worth $1,086,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 42.39% of the company's stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.